Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor & fibroid embolization cases in Utah: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (118 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 116 | 41% |
| 2020 | 1 | 71 | 44% |
| 2021 | 1 | 78 | 48% |
| 2022 | 1 | 90 | 51% |
| 2023 | 1 | 66 | 54% |
| 2024 | 2 | 100 | 57% |
| 2025 from claims | – | 153 123–179 | 59% |
| 2026 forecast | – | 159 125–200 | 60% |
| 2027 forecast | – | 166 123–219 | 61% |
| 2028 forecast | – | 173 122–239 | 62% |
| 2029 forecast | – | 180 123–258 | 62% |
| 2030 forecast | – | 188 123–279 | 63% |
Chemo- and radioembolization of liver tumors, uterine fibroid and other organ embolization (one code covers all). Professional codes (what the surgeon bills): CPT 37243.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Utah; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 10% inpatient hospital, 52% hospital outpatient, 38% office. The share outside the hospital has moved +38 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 34 | 1,753+3.4%/yr | +3.4%/yr | 0.5 | 40% | 4,240 in 2030+16%/yr |
| Arizona | 11 | 723+24%/yr | +24%/yr | 1.0 | 78% | 1,640 in 2030+15%/yr |
| Colorado | 4 | 415+7.6%/yr | +7.6%/yr | 0.9 | 70% | 820 in 2030+12%/yr |
| Oregon | 6 | 355+8.7%/yr | +8.7%/yr | 0.9 | 30% | 460 in 2030+4.5%/yr |
| Washington | 8 | 333+2.3%/yr | +2.3%/yr | 0.4 | 39% | 490 in 2030+6.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 20 | 1,028−3.6%/yr | −3.6%/yr | 5.00.8× | 9% | 990 in 2030−0.7%/yr |
| Tumor ablation | 1 | 173+29%/yr | +29%/yr | 0.83.1× | 79% | 280 in 2030+8.3%/yr |
Tumor & fibroid embolization in every state, and its device makers · Every procedure market in Utah · Every state · Compare with California
Pulse Biosciences leads with 55% of company spending on these surgeons in 2025, +30 pts on 2024.
In 2025, 16 companies reported engagement with Utah’s surgeons worth $156K in consulting, speaking, meals and travel tied to these products, about $78K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 16 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.